EDG-15400 / Edgewise Therap - LARVOL DELTA

EDG-15400, a Novel Sarcomere Modulator, Prevents the Development of Diastolic Dysfunction in the ZSF1 Rat Model of HFpEF (AHA 2026) - "Abstract is embargoed at this time."

Preclinical • Cardiovascular

A Study of EDG-15400 in Adults With Heart Failure With Preserved Ejection Fraction (EQUINOX-HFpEF) (clinicaltrials.gov) - P2 | N=90 | Recruiting | Sponsor: Edgewise Therapeutics, Inc.

New P2 trial • Cardiovascular • Congestive Heart Failure • Heart Failure

A Study of EDG-15400 in Healthy Adults (clinicaltrials.gov) - P1 | N=84 | Completed | Sponsor: Edgewise Therapeutics, Inc. | Recruiting ➔ Completed

Trial completion

Acute administration of EDG-15400, a novel cardiac sarcomere modulator, improves left ventricular compliance and cardiac reserve in a genetic mini-pig model of HCM with relevance to HFpEF (HEART FAILURE 2026) - "EDG-15400 was administered over a 1-5 min IV bolus, and data were collected both at resting baseline and following β-adrenergic (β-AR) stress (dobutamine, 2 ug/kg/min IV). Acute EDG-15400 treatment demonstrated potent improvement in LV diastolic function and cardiac reserve without impairing systolic performance in a mini-pig model of nHCM with translational relevance to HFpEF. These beneficial cardiac effects were observed without a parallel decrease in LV contractility, contrasting with current cardiac myosin inhibitors and providing support for clinical investigation of EDG-15400 in HFpEF beyond supranormal LV ejection fractions."

Compliance • Preclinical • Cardiomyopathy • Cardiovascular • Congestive Heart Failure • Heart Failure • Hypertrophic Cardiomyopathy • Non-obstructive Hypertrophic Cardiomyopathy • MYH7

A Study of EDG-15400 in Healthy Adults (clinicaltrials.gov) - P1 | N=108 | Recruiting | Sponsor: Edgewise Therapeutics, Inc.

New P1 trial